logo
logo
Sign in

The Increased Availability Of Reversal Agents Is Driving The Anticoagulant Reversal Drugs Market

avatar
Sushil Mahalle's Articles
The Increased Availability Of Reversal Agents Is Driving The Anticoagulant Reversal Drugs Market

The anticoagulant reversal drugs market is also driven by the increasing availability of reversal agents for DOACs, which were introduced to the market in the past decade. DOACs, such as dabigatran, rivaroxaban, apixaban, and edoxaban, are increasingly used as alternatives to warfarin for the prevention of thrombotic events. However, unlike warfarin, which can be reversed with vitamin K, there were no specific reversal agents for DOACs until recently. In 2015, idarucizumab was approved by the FDA as a specific reversal agent for dabigatran, and in 2018, andexanet alfa was approved for the reversal of rivaroxaban and apixaban.

 

Despite the growing demand for anticoagulant reversal drugs, the Anticoagulant Reversal Drugs Market faces several challenges, including the high cost of these therapies and the lack of awareness among healthcare professionals. Anticoagulant reversal drugs can be expensive, particularly the newer agents such as dear. A range of reversal agents are available for these anticoagulants, including acenocoumarol and phenindione which can be administered orally or via intravenous injection. Urgent reversal of parenteral and subcutaneous anticoagulants is essential for patients with clinically relevant bleeding or to avoid a potential adverse event before surgery. A combination of general measures and drug-specific management is needed, with laboratory evaluations being essential for guiding reversal decisions.

Increasing number of approval and launch of novel therapies is projected to augment growth of the global anticoagulant reversal drugs market over the forecast period. Several market players are focused on getting approvals of and launching new therapies in the market. For instance, in March 2022, AstraZeneca received approval from authorities in Japan for its Ondexxya (andexanet alfa) for patients treated with the Factor Xa inhibitors, edoxaban, rivaroxaban, or apixaban when anticoagulation reversal is required, owing to uncontrollable bleeding. 


Read More:

https://blogger-aware.blogspot.com/2023/02/anticoagulant-reversal-drugs-market-to.html

Click Here For the Anticoagulant Reversal Drugs Market Press Release

 


 

collect
0
avatar
Sushil Mahalle's Articles
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more